Prostate cancer in Asia: A collaborative report

Affiliations


Abstract

The incidence of prostate cancer (PCa) within Asian population used to be much lower than in the Western population; however, in recent years the incidence and mortality rate of PCa in some Asian countries have grown rapidly. This collaborative report summarized the latest epidemiology information, risk factors, and racial differences in PCa diagnosis, current status and new trends in surgery management and novel agents for castration-resistant prostate cancer. We believe such information would be helpful in clinical decision making for urologists and oncologists, health-care ministries and medical researchers.

Keywords: Asian population; Epidemiology; Prostate cancer; Racial differences; Risk factors; Surgery management.


Figures


Similar articles

The incidence, mortality, and risk factors of prostate cancer in Asian men.

Ha Chung B, Horie S, Chiong E.Prostate Int. 2019 Mar;7(1):1-8. doi: 10.1016/j.prnil.2018.11.001. Epub 2018 Nov 22.PMID: 30937291 Free PMC article. Review.

The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy.

Akaza H, Moore MA, Chang SJ, Cheng C, Choi HY, Esuvaranathan K, Hinotsu S, Hong SJ, Kim CS, Kim WJ, Murai M, Naito S, Soebadi D, Song JM, Umbas R, Usami M, Xia S, Yang CR.Asian Pac J Cancer Prev. 2007 Jan-Mar;8(1):3-12.PMID: 17477764

Prevalence and management of prostate cancer among East Asian men: Current trends and future perspectives.

Monn MF, Tatem AJ, Cheng L.Urol Oncol. 2016 Feb;34(2):58.e1-9. doi: 10.1016/j.urolonc.2015.09.003. Epub 2015 Oct 20.PMID: 26493449

Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.

Kelly SP, Anderson WF, Rosenberg PS, Cook MB.Eur Urol Focus. 2018 Jan;4(1):121-127. doi: 10.1016/j.euf.2017.10.014. Epub 2017 Nov 20.PMID: 29162421 Free PMC article.

Prostate cancer screening in Europe and Asia.

Zhang K, Bangma CH, Roobol MJ.Asian J Urol. 2017 Apr;4(2):86-95. doi: 10.1016/j.ajur.2016.08.010. Epub 2016 Sep 4.PMID: 29264211 Free PMC article. Review.


Cited by

The association between serum lipid profile and the prostate cancer risk and aggressiveness.

Suh J, Shin TJ, You D, Jeong IG, Hong JH, Kim CS, Ahn H.Front Oncol. 2023 May 15;13:1113226. doi: 10.3389/fonc.2023.1113226. eCollection 2023.PMID: 37256171 Free PMC article.

Association Between Statin Exposure and Incidence and Prognosis of Prostate Cancer: A Meta-analysis Based on Observational Studies.

Cao Z, Yao J, He Y, Lou D, Huang J, Zhang Y, Chen M, Zhou Z, Zhou X.Am J Clin Oncol. 2023 Jul 1;46(7):323-334. doi: 10.1097/COC.0000000000001012. Epub 2023 May 5.PMID: 37143189 Free PMC article.

Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting.

Pejčić T, Todorović Z, Đurašević S, Popović L.Int J Mol Sci. 2023 Feb 2;24(3):2939. doi: 10.3390/ijms24032939.PMID: 36769263 Free PMC article. Review.

Adjuvant radiotherapy in patients with node-positive prostate cancer after radical prostatectomy.

Chen H, Qu M, Shi H, Dong Z, Wang Y, Gao X.J Cancer Res Clin Oncol. 2023 Jul;149(8):4925-4932. doi: 10.1007/s00432-022-04409-z. Epub 2022 Oct 29.PMID: 36308526

Review of prostate cancer genomic studies in Africa.

Samtal C, El Jaddaoui I, Hamdi S, Bouguenouch L, Ouldim K, Nejjari C, Ghazal H, Bekkari H.Front Genet. 2022 Oct 11;13:911101. doi: 10.3389/fgene.2022.911101. eCollection 2022.PMID: 36303548 Free PMC article. Review.


KMEL References


References

  1.  
    1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA: Cancer J Clin. 2013;63:11–30. - PubMed
  2.  
    1. Center M.M., Jemal A., Lortet-Tieulent J., Ward E., Ferlay J., Brawley O. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–1092. - PubMed
  3.  
    1. Ferlay J.S.I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M. International Agency for Research on Cancer; Lyon, France: 2013. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11.http://globocan.iarc.fr [Internet] Available from: [accessed 28.08.14]
  4.  
    1. Pramesh C.S., Badwe R.A., Borthakur B.B., Chandra M., Raj E.H., Kannan T. Delivery of affordable and equitable cancer care in India. Lancet Oncol. 2014;15:e223–e233. - PubMed
  5.  
    1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: Cancer J Clin. 2011;61:69–90. - PubMed
  6.  
    1. Ito K. Prostate cancer in Asian men. Nat Rev Urol. 2014;11:197–212. - PubMed
  7.  
    1. He J.C.W. China Military Medical Science Press; Beijing: 2013. Chinese cancer registry annual report 2012.
  8.  
    1. Jung K.W., Won Y.J., Kong H.J., Oh C.M., Lee D.H., Lee J.S. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014;46:109–123. - PMC - PubMed
  9.  
    1. Magi-Galluzzi C., Tsusuki T., Elson P., Simmerman K., LaFargue C., Esgueva R. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate. 2011;71:489–497. - PubMed
  10.  
    1. Ren S., Peng Z., Mao J.H., Yu Y., Yin C., Gao X. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res. 2012;22:806–821. - PMC - PubMed
  11.  
    1. Rubin M.A., Maher C.A., Chinnaiyan A.M. Common gene rearrangements in prostate cancer. J Clin Oncol. 2011;29:3659–3668. - PMC - PubMed
  12.  
    1. Leinonen K.A., Saramaki O.R., Furusato B., Kimura T., Takahashi H., Egawa S. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:2333–2444. - PMC - PubMed
  13.  
    1. Konishi N., Hiasa Y., Tsuzuki T., Tao M., Enomoto T., Miller G.J. Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate. 1997;30:53–57. - PubMed
  14.  
    1. Ren G., Liu X., Mao X., Zhang Y., Stankiewicz E., Hylands L. Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer. Genes Chromosom Cancer. 2012;51:1014–1023. - PubMed
  15.  
    1. Eeles R.A., Olama A.A., Benlloch S., Saunders E.J., Leongamornlert D.A., Tymrakiewicz M. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013;45:385–391. 91e1–2. - PMC - PubMed
  16.  
    1. Takata R., Akamatsu S., Kubo M., Takahashi A., Hosono N., Kawaguchi T. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet. 2010;42:751–754. - PubMed
  17.  
    1. Akamatsu S., Takata R., Haiman C.A., Takahashi A., Inoue T., Kubo M. Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet. 2012;44:426–429. S1. - PubMed
  18.  
    1. Xu J., Mo Z., Ye D., Wang M., Liu F., Jin G. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet. 2012;44:1231–1235. - PMC - PubMed
  19.  
    1. Shan J., Al-Rumaihi K., Rabah D., Al-Bozom I., Kizhakayil D., Farhat K. Genome scan study of prostate cancer in Arabs: identification of three genomic regions with multiple prostate cancer susceptibility loci in Tunisians. J Transl Med. 2013;11:121. - PMC - PubMed
  20.  
    1. Nam K.C., Jo C., Lee M. Meat products and consumption culture in the East. Meat Sci. 2010;86:95–102. - PubMed
  21.  
    1. Rastogi T., Devesa S., Mangtani P., Mathew A., Cooper N., Kao R. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol. 2008;37:147–160. - PubMed
  22.  
    1. Zhang J., Dhakal I.B., Zhao Z., Li L. Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev. 2012;21:480–489. - PubMed
  23.  
    1. Andriole G.L., Crawford E.D., Grubb R.L., 3rd, Buys S.S., Chia D., Church T.R. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125–132. - PMC - PubMed
  24.  
    1. Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328. - PubMed
  25.  
    1. Liu Z.Y., Sun Y.H., Xu C.L., Gao X., Zhang L.M., Ren S.C. Age-specific PSA reference ranges in Chinese men without prostate cancer. Asian J Androl. 2009;11:100–103. - PMC - PubMed
  26.  
    1. Lim J., Bhoo-Pathy N., Sothilingam S., Malek R., Sundram M., Hisham Bahadzor B. Ethnicity is an independent determinant of age-specific PSA level: findings from a multiethnic Asian setting. PLoS One. 2014;9:e104917. - PMC - PubMed
  27.  
    1. Lin T.P., Huang W.J., Chen K.K. Differentiation of benign prostatic hyperplasia from prostate cancer using prostate specific antigen dynamic profile after transrectal prostate biopsy. J Urol. 2004;171:2226–2229. - PubMed
  28.  
    1. Oesterling J.E., Jacobsen S.J., Chute C.G., Guess H.A., Girman C.J., Panser L.A. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270:860–864. - PubMed
  29.  
    1. Wu T.T., Huang J.K. The clinical usefulness of prostate-specific antigen (PSA) level and age-specific PSA reference ranges for detecting prostate cancer in Chinese. Urol Int. 2004;72:208–211. - PubMed
  30.  
    1. Choi Y.D., Kang D.R., Nam C.M., Kim Y.S., Cho S.Y., Kim S.J. Age-specific prostate-specific antigen reference ranges in Korean men. Urology. 2007;70:1113–1116. - PubMed
  31.  
    1. Oesterling J.E., Kumamoto Y., Tsukamoto T., Girman C.J., Guess H.A., Masumori N. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol. 1995;75:347–353. - PubMed
  32.  
    1. Imai K., Ichinose Y., Kubota Y., Yamanaka H., Sato J. Diagnostic significance of prostate specific antigen and the development of a mass screening system for prostate cancer. J Urol. 1995;154:1085–1089. - PubMed
  33.  
    1. Malati T., Kumari G.R. Racial and ethnic variation of PSA in global population: age specific reference intervals for serum prostate specific antigen in healthy South Indian males. Indian J Clin Biochem. 2004;19:132–137. - PMC - PubMed
  34.  
    1. Abdrabo A.A., Fadlalla A.I., Fadl-Elmula I.M. Age-specific reference range for serum prostate-specific antigen in Sudanese men. Saudi Med J. 2011;32:930–932. - PubMed
  35.  
    1. Kamal B.A., Ali G.A., Taha S.A. Prostate specific antigen reference ranges in Saudi men. Saudi Med J. 2003;24:665–668. - PubMed
  36.  
    1. Saw S., Aw T.C. Age-related reference intervals for free and total prostate-specific antigen in a Singaporean population. Pathology. 2000;32:245–249. - PubMed
  37.  
    1. Kehinde E.O., Mojiminiyi O.A., Sheikh M., Al-Awadi K.A., Daar A.S., Al-Hunayan A. Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men. BJU Int. 2005;96:308–312. - PubMed
  38.  
    1. Khezri A.A., Shirazi M., Ayatollahi S.M., Lotfi M., Askarian M., Ariafar A. Age specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian men. Iran J Immunol. 2009;6:40–48. - PubMed
  39.  
    1. Takahashi H., Epstein J.I., Wakui S., Yamamoto T., Furusato B., Zhang M. Differences in prostate cancer grade, stage, and location in radical prostatectomy specimens from United States and Japan. Prostate. 2014;74:321–325. - PubMed
  40.  
    1. Peyromaure M., Debre B., Mao K., Zhang G., Wang Y., Sun Z. Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol. 2005;174:1794–1797. - PubMed
  41.  
    1. Vickers A.J., Cronin A.M., Roobol M.J., Hugosson J., Jones J.S., Kattan M.W. The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res. 2010;16:4374–4381. - PMC - PubMed
  42.  
    1. Kimura T. East meets west: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians. Chin J Cancer. 2012;31:421–429. - PMC - PubMed
  43.  
    1. Terao C., Terada N., Matsuo K., Kawaguchi T., Yoshimura K., Hayashi N. A genome-wide association study of serum levels of prostate-specific antigen in the Japanese population. J Med Genet. 2014;51:530–536. - PubMed
  44.  
    1. Haese A., de la Taille A., van Poppel H., Marberger M., Stenzl A., Mulders P.F. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54:1081–1088. - PubMed
  45.  
    1. Guazzoni G., Nava L., Lazzeri M., Scattoni V., Lughezzani G., Maccagnano C. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol. 2011;60:214–222. - PubMed
  46.  
    1. Na R., Ye D., Liu F., Chen H., Qi J., Wu Y. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population. Prostate. 2014;74:1569–1575. - PubMed
  47.  
    1. Lazzeri M., Haese A., Abrate A., de la Taille A., Redorta J.P., McNicholas T. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int. 2013;112:313–321. - PubMed
  48.  
    1. Ochiai A., Okihara K., Kamoi K., Iwata T., Kawauchi A., Miki T. Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy. Int J Urol. 2011;18:200–205. - PubMed
  49.  
    1. Ochiai A., Okihara K., Kamoi K., Oikawa T., Shimazui T., Murayama S. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int. 2013;111:928–933. - PubMed
  50.  
    1. Ng C.F., Yeung R., Chiu P.K., Lam N.Y., Chow J., Chan B. The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients. Hong Kong Med J. 2012;18:459–465. - PubMed
  51.  
    1. Shen M., Chen W., Yu K., Chen Z., Zhou W., Lin X. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population. Exp Mol Pathol. 2011;90:97–100. - PubMed
  52.  
    1. Ng C.F., Chiu P.K., Lam N.Y., Lam H.C., Lee K.W., Hou S.S. The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL. Int Urol Nephrol. 2014;46:711–717. - PubMed
  53.  
    1. Ito K., Miyakubo M., Sekine Y., Koike H., Matsui H., Shibata Y. Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0–10.0 ng/mL range. World J Urol. 2013;31:305–311. - PubMed
  54.  
    1. Ren S., Wang F., Shen J., Sun Y., Xu W., Lu J. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013;49:2949–2959. - PubMed
  55.  
    1. Jiang H., Liu F., Wang Z., Na R., Zhang L., Wu Y. Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs. Prostate. 2013;73:1651–1659. - PMC - PubMed
  56.  
    1. Ueda K., Tatsuguchi A., Saichi N., Toyama A., Tamura K., Furihata M. Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide. J Proteome Res. 2013;12:4497–4506. - PubMed
  57.  
    1. Li X.M., Zhang L., Li J., Li Y., Wang H.L., Ji G.Y. Measurement of serum zinc improves prostate cancer detection efficiency in patients with PSA levels between 4 ng/mL and 10 ng/mL. Asian J Androl. 2005;7:323–328. - PubMed
  58.  
    1. Arita T., Ichikawa D., Konishi H., Komatsu S., Shiozaki A., Shoda K. Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res. 2013;33:3185–3193. - PubMed
  59.  
    1. Reiner W.G., Walsh P.C. An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery. J Urol. 1979;121:198–200. - PubMed
  60.  
    1. Schuessler W.W., Schulam P.G., Clayman R.V., Kavoussi L.R. Laparoscopic radical prostatectomy: initial short-term experience. Urology. 1997;50:854–857. - PubMed
  61.  
    1. Gao X., Qiu J.G., Wang J.G. Laparoscopic radical prostatectomy: report of the first case. Chin J Urol. 2002;23:59.
  62.  
    1. Kawabata G., Hara I., Hara S., Isotani S., Sakai Y., Wada Y. Laparoscopic radical prostatectomy: initial 17 case report. Nihon Hinyokika Gakkai zasshi. 2001;92:647–655. - PubMed
  63.  
    1. Wolfram M., Brautigam R., Engl T., Bentas W., Heitkamp S., Ostwald M. Robotic-assisted laparoscopic radical prostatectomy: the Frankfurt technique. World J Urol. 2003;21:128–132. - PubMed
  64.  
    1. Wang W., Gao J., Xu X., Dong J., Zhu J. Proceedings of the 16th Chinese Urology Association Annual Meeting, Chengdu, China. Sep 18th, 2009. Extraperitoneal robot-assisted laparoscopic radical prostatectomy.
  65.  
    1. Chen M.K., Luo Y., Zhang H., Qiu J.G., Wen X.Q., Pang J. Laparoscopic radical prostatectomy plus extended lymph nodes dissection for cases with non-extra node metastatic prostate cancer: 5-year experience in a single Chinese institution. J Cancer Res Clin Oncol. 2013;139:871–878. - PubMed
  66.  
    1. Zheng T., Zhang X., Ma X., Li H.Z., Gao J.P., Cai W. Oncological and functional results of extraperitoneal laparoscopic radical prostatectomy. Oncol Lett. 2012;4:351–357. - PMC - PubMed
  67.  
    1. Wen X.Q., Huang W.T., Situ J., Hu C., Ye C.W., Gao X. Single-port laparoscopic radical prostatectomy: initial experience and technical points to reduce its difficulties. Chin Med J. 2011;124:4092–4095. - PubMed
  68.  
    1. Namiki S., Kaiho Y., Mitsuzuka K., Saito H., Yamada S., Nakagawa H. Long-term quality of life after radical prostatectomy: 8-year longitudinal study in Japan. Int J Urol. 2014;21:1220–1226. - PubMed
  69.  
    1. Mishra S., Agrawal V., Khatri N., Sharma R., Kurien A., Ganpule A. Laparoscopic radical prostatectomy: oncological outcome analysis from a single-center Indian experience of 6 years. Indian J Urol. 2012;28:32–36. - PMC - PubMed
  70.  
    1. Koo K.C., Tuliao P., Yoon Y.E., Chung B.H., Hong S.J., Yang S.C. Robot-assisted radical prostatectomy in the Korean population: a 5-year propensity-score matched comparative analysis versus open radical prostatectomy. Int J Urol. 2014;21:781–785. - PubMed
  71.  
    1. Gao X., Pang J., Si-tu J., Luo Y., Zhang H., Li L.Y. Single-port transvesical laparoscopic radical prostatectomy for organ-confined prostate cancer: technique and outcomes. BJU Int. 2013;112:944–952. - PubMed
  72.  
    1. Lim S.K., Kim K.H., Shin T.Y., Han W.K., Chung B.H., Hong S.J. Retzius-sparing robot-assisted laparoscopic radical prostatectomy: combining the best of retropubic and perineal approaches. BJU Int. 2014;114:236–244. - PubMed
  73.  
    1. Ficarra V., Cavalleri S., Novara G., Aragona M., Artibani W. Evidence from robot-assisted laparoscopic radical prostatectomy: a systematic review. Eur Urol. 2007;51:45–56. - PubMed
  74.  
    1. Denis L.J. Staging and prognosis of prostate cancer. Eur Urol. 1993;24(Suppl. 2):13–18. - PubMed
  75.  
    1. Zlotta A.R., Egawa S., Pushkar D., Govorov A., Kimura T., Kido M. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst. 2013;105:1050–1058. - PubMed